Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

This study is testing a combination of four drugs — bortezomib, isatuximab, cyclophosphamide, and dexamethasone — as an initial treatment for patients newly diagnosed with multiple myeloma (a type of blood cancer) before they undergo a stem cell transplant. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with multiple myeloma (confirmed by bone marrow test and organ damage criteria) - You are eligible for high-dose chemotherapy and stem cell transplant - You have received little to no prior treatment for multiple myeloma (limited short-term treatment is acceptable) - You are in reasonably good overall health **You may NOT be eligible if...** - You have already received extensive prior treatment for multiple myeloma - You have a different type of plasma cell disorder (not myeloma) - You are not a candidate for stem cell transplant - You are pregnant or breastfeeding - You have serious uncontrolled infections or organ problems Talk to your doctor to see if this trial is right for you.